The effectiveness of the response of NSCLC patients to anti‐PD‐1/PD‐L1 immunotherapy requires functional systemic CD4 immunity at the baseline level, which could enhance the proliferative capacities of CD8+ T cells.81 The gene discussed is CD4; the disease is non-small cell lung carcinoma.